The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection

被引:63
作者
Carothers, John J.
Bruce, Michael G.
Hennessy, Thomas W.
Bensler, Michael
Morris, Julie M.
Reasonover, Alisa L.
Hurlburt, Debby A.
Parkinson, Alan J.
Coleman, John M.
McMahon, Brian J.
机构
[1] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Infect Dis, Anchorage, AK 99508 USA
[2] Alaska Native Med Ctr, Anchorage, AK USA
[3] Univ Washington, Sch Med, Seattle, WA 98195 USA
关键词
D O I
10.1086/510074
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The relationship between prior fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection is unknown. Among 125 enrolled patients, 8.8% had H. pylori isolates that were resistant to levofloxacin. Levofloxacin resistance was associated with any prior fluoroquinolone use over the previous 10 years and with the total number of fluoroquinolone courses prescribed (P < .001).
引用
收藏
页码:E5 / E8
页数:4
相关论文
共 26 条
[1]   Epidemiological features of Helicobacter pylori infection in developing countries [J].
Bardhan, PK .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :973-978
[2]  
Best L, 2004, GASTROENTEROLOGY, V126, pA189
[3]   Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999) [J].
Cabrita, J ;
Oleastro, M ;
Matos, R ;
Manhente, A ;
Cabral, J ;
Barros, R ;
Lopes, AI ;
Ramalho, P ;
Neves, BC ;
Guerreiro, AS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :1029-1031
[4]   High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection [J].
Cammarota, G ;
Martino, A ;
Pirozzi, G ;
Cianci, R ;
Branca, G ;
Nista, EC ;
Cazzato, A ;
Cannizzaro, O ;
Miele, L ;
Grieco, A ;
Gasbarrini, A ;
Gasbarrini, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (07) :789-795
[5]   High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication [J].
Cammarota, G ;
Cianci, R ;
Cannizzaro, O ;
Martino, A ;
Fedeli, P ;
Lecca, PG ;
di Caro, S ;
Cesaro, P ;
Branca, G ;
Gasbarrini, G .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2004, 38 (02) :110-114
[6]   New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures:: a pilot study [J].
Coelho, LGV ;
Moretzsohn, LD ;
Vieira, WLS ;
Gallo, MA ;
Passos, MCF ;
Cindr, JM ;
Cerqueira, MC ;
Vitiello, L ;
Ribeiro, ML ;
Mendonça, S ;
Pedrazzoli, J ;
Castro, LP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (06) :783-787
[7]   Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States [J].
Duck, WM ;
Sobel, J ;
Pruckler, JM ;
Song, OS ;
Swerdlow, D ;
Friedman, C ;
Sulka, A ;
Swaminathan, B ;
Taylor, T ;
Hoekstra, M ;
Griffin, P ;
Smoot, D ;
Peek, R ;
Metz, DC ;
Bloom, PB ;
Goldschmid, S ;
Parsonnet, J ;
Triadafilopoulos, G ;
Perez-Perez, GI ;
Vakil, N ;
Ernst, P ;
Czinn, S ;
Dunne, D ;
Gold, BD .
EMERGING INFECTIOUS DISEASES, 2004, 10 (06) :1088-1094
[8]   In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children [J].
Fujimura, S ;
Kato, S ;
Iinuma, K ;
Watanabe, A .
JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (10) :1019-1022
[9]   A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses [J].
Gatta, L ;
Zullo, A ;
Perna, F ;
Ricci, C ;
De Francesco, V ;
Tampieri, A ;
Bernabucci, V ;
Cavina, M ;
Hassan, C ;
Ierardi, E ;
Morini, S ;
Vaira, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (01) :45-49
[10]   EPIDEMIOLOGY OF HELICOBACTER-PYLORI IN AN ASYMPTOMATIC POPULATION IN THE UNITED-STATES - EFFECT OF AGE, RACE, AND SOCIOECONOMIC-STATUS [J].
GRAHAM, DY ;
MALATY, HM ;
EVANS, DG ;
EVANS, DJ ;
KLEIN, PD ;
ADAM, E .
GASTROENTEROLOGY, 1991, 100 (06) :1495-1501